{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:55:24Z","timestamp":1791262524944,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03043-4","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:31:07Z","timestamp":1791261067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BEAM versus EAM, FEAM, BeEAM, and TEAM: exploring conditioning strategies in autologous stem cell transplantation for Hodgkin lymphoma a retrospective study of the LWP of EBMT"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-9252","authenticated-orcid":false,"given":"Annalisa","family":"Paviglianiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Fekom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-9138","authenticated-orcid":false,"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-890X","authenticated-orcid":false,"given":"Malek","family":"Benakli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-4401","authenticated-orcid":false,"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pierluigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3638-0650","authenticated-orcid":false,"given":"Raffaella","family":"Cerretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9428","authenticated-orcid":false,"given":"Jean","family":"El-Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saveria","family":"Capria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6539-226X","authenticated-orcid":false,"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1545-3137","authenticated-orcid":false,"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-499X","authenticated-orcid":false,"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3043_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","volume":"60","author":"R Greco","year":"2025","unstructured":"Greco R, Ruggeri A, McLornan DP, Snowden JA, Alexander T, Angelucci E, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transpl. 2025;60:1499\u20131525.","journal-title":"Bone Marrow Transpl"},{"key":"3043_CR2","doi-asserted-by":"publisher","first-page":"102594","DOI":"10.1016\/j.tranon.2025.102594","volume":"63","author":"H Tian","year":"2026","unstructured":"Tian H, Wang R, Cong D, Bai Y, Zhang W. Evolution of conditioning regimens prior to autologous stem cell transplantation in lymphoma patients. Transl Oncol. 2026;63:102594.","journal-title":"Transl Oncol"},{"key":"3043_CR3","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1080\/10428194.2016.1185785","volume":"57","author":"A Isidori","year":"2016","unstructured":"Isidori A, Christofides A, Visani G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma. 2016;57:2499\u2013509.","journal-title":"Leuk Lymphoma"},{"key":"3043_CR4","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1111\/ajco.12610","volume":"13","author":"Y Shi","year":"2017","unstructured":"Shi Y, Liu P, Zhou S, Yang J, Han X, He X, et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: efficacy and toxicity. Asia Pac J Clin Oncol. 2017;13:e423\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"key":"3043_CR5","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41409-018-0196-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H, Dreger P, Sureda A, Hermine O, et al. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party. Bone Marrow Transpl. 2018;53:1553\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"3043_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","volume":"87","author":"JC Jo","year":"2008","unstructured":"Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008;87:43\u20138.","journal-title":"Ann Hematol"},{"key":"3043_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:1046\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3043_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.clml.2013.03.009","volume":"13","author":"BM William","year":"2013","unstructured":"William BM, Loberiza FR, Whalen V, Bierman PJ, Bociek RG, Vose JM, et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13:417\u201323.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3043_CR9","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","volume":"118","author":"G Visani","year":"2011","unstructured":"Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients. Blood. 2011;118:3419\u201325.","journal-title":"Blood"},{"key":"3043_CR10","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1182\/blood-2014-08-596668","volume":"124","author":"G Visani","year":"2014","unstructured":"Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood. 2014;124:3029\u201331.","journal-title":"Blood"},{"key":"3043_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ajh.25077","volume":"93","author":"SP Chantepie","year":"2018","unstructured":"Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol. 2018;93:729\u201335.","journal-title":"Am J Hematol"},{"key":"3043_CR12","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1080\/10428194.2017.1403019","volume":"59","author":"K Saleh","year":"2018","unstructured":"Saleh K, Danu A, Koscielny S, Legoupil C, Pilorge S, Castilla-Llorente C, et al. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leuk Lymphoma. 2018;59:2580\u20137.","journal-title":"Leuk Lymphoma"},{"key":"3043_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93516-x","volume":"11","author":"L Hahn","year":"2021","unstructured":"Hahn L, Lim H, Dusyk T, Sabry W, Elemary M, Stakiw J, et al. BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy. Sci Rep. 2021;11:14071.","journal-title":"Sci Rep"},{"key":"3043_CR14","first-page":"113","volume":"22","author":"A Frankiewicz","year":"2018","unstructured":"Frankiewicz A, Sadu\u015b-Wojciechowska M, Najda J, Czerw T, Mendrek W, Sobczyk-Kruszelnicka M, et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemp Oncol Pozn Pol. 2018;22:113\u20137.","journal-title":"Contemp Oncol Pozn Pol"},{"key":"3043_CR15","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1002\/ajh.25340","volume":"94","author":"M Lucijanic","year":"2019","unstructured":"Lucijanic M, Prka Z, Jaksic O, Mitrovic Z, Vrkljan A, Pejsa V. Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality. Am J Hematol. 2019;94:E42\u20133.","journal-title":"Am J Hematol"},{"key":"3043_CR16","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1080\/10428194.2020.1811863","volume":"61","author":"A Glover","year":"2020","unstructured":"Glover A, Fox CP, McMillan A, Beech A, Martinez-Calle N, Griffiths C, et al. A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphoma. Leuk Lymphoma. 2020;61:3529\u201331.","journal-title":"Leuk Lymphoma"},{"key":"3043_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.hemonc.2020.11.003","volume":"14","author":"NI AlJohani","year":"2021","unstructured":"AlJohani NI, Nasani M, Ahmed HE, Ur Rehman J, Nawaz A, Alzahrani Z, et al. Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a retrospective single-center study. Hematol Oncol Stem Cell Ther. 2021;14:327\u201335.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"3043_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00277-016-2900-y","volume":"96","author":"S Gilli","year":"2017","unstructured":"Gilli S, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, et al. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Ann Hematol. 2017;96:421\u20139.","journal-title":"Ann Hematol"},{"key":"3043_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41409-018-0328-9","volume":"54","author":"ES Tsang","year":"2019","unstructured":"Tsang ES, Villa D, Loscocco F, Visani G, Power M, Guiducci B, et al. High-dose Benda-EAM versus BEAM in patients with relapsed\/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transpl. 2019;54:481\u20134.","journal-title":"Bone Marrow Transpl"},{"key":"3043_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3389\/fonc.2019.00892","volume":"9","author":"A Colita","year":"2019","unstructured":"Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, et al. LEAM vs. BEAM vs. CLV conditioning regimen for autologous stem cell transplantation in malignant lymphomas. retrospective comparison of toxicity and efficacy on 222 patients in the first 100 days after transplant, on behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019;9:892.","journal-title":"Front Oncol"},{"key":"3043_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/bmt.2009.114","volume":"45","author":"M Musso","year":"2010","unstructured":"Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F, et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transpl. 2010;45:123\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"3043_CR22","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.bbmt.2018.05.018","volume":"24","author":"J Olivieri","year":"2018","unstructured":"Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from fondazione Italiana Linfomi. Biol Blood Marrow Transpl. 2018;24:1814\u201322.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3043_CR23","doi-asserted-by":"publisher","first-page":"1369601","DOI":"10.3389\/fonc.2024.1369601","volume":"14","author":"E Benedetti","year":"2024","unstructured":"Benedetti E, Traverso G, Pucci G, Morganti R, Bramanti E, Cavallo F, et al. Prospective study on the impact of BEAM versus FEAM conditioning on occurrence of neutropenic enterocolitis and on transplant outcome in lymphoma patients. Front Oncol. 2024;14:1369601.","journal-title":"Front Oncol"},{"key":"3043_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/bmt.2015.273","volume":"51","author":"L Sellner","year":"2016","unstructured":"Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transpl. 2016;51:212\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"3043_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.transproceed.2022.12.001","volume":"55","author":"B Deveci","year":"2023","unstructured":"Deveci B, Ate\u015fo\u011flu EB, Bayrak E, Kublashvili G, Topta\u015f T, Saba R, et al. Comparative efficacy and safety of beam and team conditioning regimens for autologous stem cell transplantation in lymphoma patients. Transpl Proc. 2023;55:235\u201341.","journal-title":"Transpl Proc"},{"key":"3043_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/ejh.14118","volume":"112","author":"RF Gherman","year":"2024","unstructured":"Gherman RF, Ewald S, Ihorst G, Str\u00fc\u00dfmann T, Zeiser R, W\u00e4sch R, et al. Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning. Eur J Haematol. 2024;112:350\u20139.","journal-title":"Eur J Haematol"},{"key":"3043_CR27","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1080\/10428194.2020.1765238","volume":"61","author":"F Marchesi","year":"2020","unstructured":"Marchesi F, Capria S, Pedata M, Terrenato I, Ballotta L, Riccardi C, et al. BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant. Leuk Lymphoma. 2020;61:2238\u201341.","journal-title":"Leuk Lymphoma"},{"key":"3043_CR28","doi-asserted-by":"publisher","first-page":"102318","DOI":"10.1016\/j.eclinm.2023.102318","volume":"66","author":"F Keil","year":"2023","unstructured":"Keil F, M\u00fcller AMS, Berghold A, Riedl R, Buxhofer-Ausch V, Schuster J, et al. BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial. EClinicalMedicine. 2023;66:102318.","journal-title":"EClinicalMedicine"},{"key":"3043_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bjh.13803","volume":"172","author":"M Musso","year":"2016","unstructured":"Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, et al. Improved outcome of patients with relapsed\/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol. 2016;172:111\u201321.","journal-title":"Br J Haematol"},{"key":"3043_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/bmt.2009.318","volume":"45","author":"M Musso","year":"2010","unstructured":"Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transpl. 2010;45:1147\u201353.","journal-title":"Bone Marrow Transpl"},{"key":"3043_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41409-018-0120-x","volume":"53","author":"F Marchesi","year":"2018","unstructured":"Marchesi F, Capria S, Giannarelli D, Trisolini SM, Ansuinelli M, Caputo MD, et al. BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. Bone Marrow Transpl. 2018;53:1051\u20134.","journal-title":"Bone Marrow Transpl"},{"key":"3043_CR32","first-page":"451.e1","volume":"29","author":"S Akhtar","year":"2023","unstructured":"Akhtar S, Rauf MS, Elhassan TAM, Khan ZA, Elshenawy MA, Maghfoor I. Impact of risk factors and long term survival analysis of patients with primary refractory hodgkin lymphoma who underwent high dose chemotherapy and autologous stem cell transplant. Transpl Cell Ther. 2023;29:451.e1\u201312.","journal-title":"Transpl Cell Ther"},{"key":"3043_CR33","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41375-022-01563-8","volume":"36","author":"A Bazarbachi","year":"2022","unstructured":"Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko-Jarosinska J, Tanase A, et al. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. Leukemia. 2022;36:1646\u201353.","journal-title":"Leukemia"},{"key":"3043_CR34","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/bjh.20044","volume":"206","author":"O Paltiel","year":"2025","unstructured":"Paltiel O, Ratnasingam S, Lee HP. Are we ignoring sex differences in haematological malignancies? A call for improved reporting. Br J Haematol. 2025;206:1315\u201329.","journal-title":"Br J Haematol"},{"key":"3043_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.26744","volume":"98","author":"C Radkiewicz","year":"2023","unstructured":"Radkiewicz C, Bruchfeld JB, Weibull CE, Jeppesen ML, Frederiksen H, Lambe M, et al. Sex differences in lymphoma incidence and mortality by subtype: a population-based study. Am J Hematol. 2023;98:23\u201330.","journal-title":"Am J Hematol"},{"key":"3043_CR36","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3390\/ijerph19042339","volume":"19","author":"D Poli","year":"2022","unstructured":"Poli D, Mozzoni P, Pinelli S, Cavallo D, Papaleo B, Caporossi L. Sex difference and benzene exposure: does it matter?. Int J Environ Res Public Health. 2022;19:2339.","journal-title":"Int J Environ Res Public Health"},{"key":"3043_CR37","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1634\/stemcells.22-5-750","volume":"22","author":"B Faiola","year":"2004","unstructured":"Faiola B, Fuller ES, Wong VA, Pluta L, Abernethy DJ, Rose J, et al. Exposure of hematopoietic stem cells to benzene or 1,4-benzoquinone induces gender-specific gene expression. Stem Cells. 2004;22:750\u20138.","journal-title":"Stem Cells"},{"key":"3043_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46945-x","volume":"15","author":"AV Kammula","year":"2024","unstructured":"Kammula AV, Sch\u00e4ffer AA, Rajagopal PS, Kurzrock R, Ruppin E. Outcome differences by sex in oncology clinical trials. Nat Commun. 2024;15:2608.","journal-title":"Nat Commun"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03043-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03043-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03043-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:31:18Z","timestamp":1791261078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03043-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":38,"alternative-id":["3043"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03043-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PLZ reports consulting fees from MSD, AstraZeneca and Novartis, speaker bureau from Recordati, Kite Gilead, Janssen-Cilag, BMS, SOBI, MSD, Regeron, Takeda, Roche, AstraZeneca, Kyowa Kirin, Novartis, Incyte, BE ONE Med., Eli Lilly and participation as advisory board for Secura bio, Recordati, Kite Gilead, Janssen-Cilag, BMS, SOBI, MSD, Regeron, Takeda, Roche, AstraZeneca, Kyowa Kirin, Novartis, ADC Therap. Incyte, BE ONE Med. And Eli Lilly. The other authors have not conflict of interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study is based on data reported to the EBMT registry and all methods were performed in accordance with the relevant guidelines and regulations. EBMT centers commit to obtain informed consent according to the local regulations applicable at the time of transplantation in order to report pseudonymized data to the registry. All EBMT registry studies are performed under the supervision of the EBMT Working Parties. This study was approved by the Lymphoma Working Party (LWP) of the EBMT.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}